Quantum Genomics Société Anonyme 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Mathieu Bigois

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	2.4yrs

최근 관리 업데이트

Recent updates

CEO

Mathieu Bigois

less than a year

테뉴어

Mr. Mathieu Bigois serves as Chief Executive Officer & Chairman of the Board at Quantum Genomics Société Anonyme from 2024. Mr. Bigois serves as Investment Consultant at Ally Bridge Group. He started his c...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mathieu Bigois	CEO & Chairman of the Board	less than a year	데이터 없음	데이터 없음
George L. Bakris	Member of Scientific & Clinical Advisory Board	2.4yrs	데이터 없음	데이터 없음
Alexandre Persu	Member of Scientific & Clinical Advisory Board	no data	데이터 없음	데이터 없음
Keith Ferdinand	Member of Scientific & Clinical Advisory Board	8.8yrs	데이터 없음	데이터 없음
Gregory Lip	Member of Scientific & Clinical Advisory Board	2.4yrs	데이터 없음	데이터 없음
Atul Pathak	Member of Scientific & Clinical Advisory Board	2.4yrs	데이터 없음	데이터 없음
Pascal Ghoson	Director	less than a year	데이터 없음	데이터 없음
Laurent Narbonne	Director	less than a year	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

경험이 풍부한 이사회: 2QG 의 이사회는 경험(평균 재직 기간 2.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Quantum Genomics Société Anonyme 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Quantum Genomics Announces the Appointment of Its New Scientific Advisory Board

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

No independent directors

Quantum Genomics Société Anonyme Announces Resignation of Jean-Paul Kress from the Board

Recent updates

New minor risk - Financial data availability

New major risk - Shareholder dilution

New major risk - Shareholder dilution

New major risk - Financial position

Full year 2022 earnings released

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, Fresh and Is Redirecting to New Developments

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

First half 2022 earnings released: EPS: €0 (vs €0.23 loss in 1H 2021)

Quantum Genomics Announces the Appointment of Its New Scientific Advisory Board

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

No independent directors

Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

Quantum Genomics Announces Granting of New Patents Protecting QGC606

Quantum Genomics Société Anonyme announced that it expects to receive $2 million in funding from Gulf Pharmaceutical Industries P.S.C.

No longer forecast to breakeven

Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat

Quantum Genomics Société Anonyme announced that it has received €0.87 million in funding from Orient EuroPharma Co., Ltd.

Quantum Genomics Launches Phase III Pivotal REFRESH Study in Difficult-to-treat/Resistant Hypertension with Once-a-day Formulation of Firibastat

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran

Quantum Genomics Signs Strategic Contract with Delpharm

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm

New 90-day high: €4.02

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton Pharmaceuticals

New 90-day high: €3.26

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical to Develop and Commercialize Firibastat in Greater China Region, Hong Kong and Macao

Quantum Genomics Société Anonyme Announces Resignation of Jean-Paul Kress from the Board

New 90-day high: €2.93

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Orient EuroPharma (OEP)

New 90-day low - €2.36

New 90-day low - €2.50

CEO

테뉴어

이사회 구성원

평균 재임 기간